At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
PVS-10200biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Dose Escalation Safety Study of PVS-10200 for the Treatment of Restenosis in Patients Undergoing Minimally Invasive Peripheral Revascularization (TRIUMPH)
In Brief
A Phase 2 clinical trial evaluating PVS-10200 for Peripheral Artery Disease. Completed, enrolled 21 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic cellular therapy, delivered as a single injection following percutaneous transluminal ("balloon") angioplasty and stent placement for the treatment of peripheral artery disease (PAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Artery Disease
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartApr 2010
Primary CompletionJun 2012
Study CompletionOct 2012
TodayJul 2026
First PostedApr 6, 2010
Enrollment StartApr 30, 2010
Primary CompletionJun 30, 2012
Study CompletionOct 31, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16.2 years ago
Interventions
PVS-10200biological
PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.